Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX005N in Moderate-to-Severe Atopic Dermatitis (Phase II)
CTR20221723Phase 2Completed
- Sponsor
- Qyuns Therapeutics
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QX005N in atopic dermatitis (AD), sponsored by Qyuns Therapeutics. Started Jul 2022; status: completed.
02
Drugs
QX005N
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20221723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221723.